Methods	Design: placebo-controlled parallel trial.
Participants	Participants: outpatients with repeated suicidal attempts but without major depression Sex: 37 male; 54 female (data not extractable for any AsPD subgroup; see note 1) Age: mean 34.1 (SD 11.6) and 37.1 (SD 13.0) years (data not extractable for any AsPD subgroup; see note 1) Unit of allocation: individual participant. Number randomised: 91 (paroxetine, n = 46; placebo, n = 44) (see note 1). Number completing: at 8 weeks (paroxetine, n = 28; placebo, n = 30); at 52 weeks (paroxetine, n = 11; placebo, n = 8) (see note 1) Setting: outpatient; 2 sites; Netherlands (Rotterdam, Leiden). Inclusion criteria: at least one previous suicide attempt; aged 18 yrs or older Exclusion criteria: major affective disorder; psychotic disorder; currently taking antidepressant or antipsychotic medication; organic mental disorder; dependency on alcohol or substances; using prohibited medication; serious physical disease; unable to co-operate Ethnicity: not reported.
Interventions	Two conditions: paroxetine/ placebo. paroxetine (oral, 40 mg, once daily) (number randomised unclear). placebo (oral, once daily) (number randomised unclear). In addition to medication, supportive psychotherapy offered weekly to fortnightly to all participants Duration of intervention: up to 52 weeks. Duration of trial: up to 52 weeks. Length of follow up: participants were not followed up beyond the end of the intervention period Dose adjustment: initial placebo washout period of 2 weeks; then 20 mg/day paroxetine for one week followed by a fixed dose of 40 mg/day for up to 52 weeks (or matching placebo)
Outcomes	Primary outcomes none. Secondary outcomes Leaving the study early: Anger: STAXI scores. Other outcomes subsequent suicide attempts; depression (Beck Depression Inventory; self report); hopelessness (Beck Hopelessness Scale, self-report)
Notes	1. study may have recruited a subgroup with AsPD as 74 participants had DSM-III-R Cluster B personality disorder, although this is unclear. No data extractable on any AsPD subgroup. Awaiting clarification from investigators

RCT: randomised controlled trial